JP2019520340A5 - - Google Patents

Download PDF

Info

Publication number
JP2019520340A5
JP2019520340A5 JP2018562993A JP2018562993A JP2019520340A5 JP 2019520340 A5 JP2019520340 A5 JP 2019520340A5 JP 2018562993 A JP2018562993 A JP 2018562993A JP 2018562993 A JP2018562993 A JP 2018562993A JP 2019520340 A5 JP2019520340 A5 JP 2019520340A5
Authority
JP
Japan
Prior art keywords
faecalibacterium
pharmaceutical composition
microbial preparation
purified
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018562993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520340A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/035449 external-priority patent/WO2017210428A1/en
Publication of JP2019520340A publication Critical patent/JP2019520340A/ja
Publication of JP2019520340A5 publication Critical patent/JP2019520340A5/ja
Pending legal-status Critical Current

Links

JP2018562993A 2016-06-01 2017-06-01 炎症性腸疾患(ibd)および他の障害を治療するための組成物および方法 Pending JP2019520340A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344053P 2016-06-01 2016-06-01
US62/344,053 2016-06-01
PCT/US2017/035449 WO2017210428A1 (en) 2016-06-01 2017-06-01 Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders

Publications (2)

Publication Number Publication Date
JP2019520340A JP2019520340A (ja) 2019-07-18
JP2019520340A5 true JP2019520340A5 (https=) 2020-08-13

Family

ID=60479147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018562993A Pending JP2019520340A (ja) 2016-06-01 2017-06-01 炎症性腸疾患(ibd)および他の障害を治療するための組成物および方法

Country Status (7)

Country Link
US (2) US20170348360A1 (https=)
EP (1) EP3462882A4 (https=)
JP (1) JP2019520340A (https=)
CN (1) CN109803534A (https=)
AU (1) AU2017274416C1 (https=)
CA (1) CA3026414A1 (https=)
WO (1) WO2017210428A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016268158B2 (en) 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
CA3211208A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
MY201921A (en) * 2017-06-16 2024-03-23 Biofermin Pharmaceutical Co Ltd Agent for preventing or treating fat-associated diseases and/or inflammation
WO2018236979A1 (en) * 2017-06-20 2018-12-27 Cornell University Probiotic compositions and methods
WO2019032573A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
JP7460531B2 (ja) 2017-12-05 2024-04-02 バイオピーエルエックス,インコーポレイティド 微生物感染を防ぐための方法および組成物
EP3725321A4 (en) * 2017-12-12 2021-09-08 Morinaga Milk Industry Co., Ltd. COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE
GB2585291B (en) * 2018-02-02 2023-07-19 Univ Hong Kong Chinese Fecal fungome and therapeutic efficacy of fecal microbiota transplantation
WO2019157566A1 (en) * 2018-02-16 2019-08-22 St Vincent's Hospital (Melbourne) Limited Compositions and methods for promoting gut health
AU2019253616A1 (en) * 2018-04-13 2020-11-05 Med-Life Discoveries Lp Long chain dicarboxylic fatty acid (LCDFA) producing microbes and uses thereof
CN110396538B (zh) * 2018-04-24 2023-05-23 深圳华大生命科学研究院 偏头痛生物标志物及其用途
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
EP3870691A4 (en) * 2018-09-13 2022-09-07 Xbiome Inc. METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
WO2020227420A1 (en) * 2019-05-06 2020-11-12 The General Hospital Corporation Monitoring and altering the gut microbiome in disease
CN114364388A (zh) * 2019-07-11 2022-04-15 安东尼·米利斯 一种增强微生物植入的肠黏膜制备方法
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
CN110541026A (zh) * 2019-08-17 2019-12-06 昆明医科大学第一附属医院 一种检测溃疡性结肠炎的生物标志物及应用
AU2020365134A1 (en) * 2019-10-18 2022-06-02 Thaena Inc. Fecal-derived sterile postbiotic composition and method therefor
EP3839072A1 (en) * 2019-12-17 2021-06-23 Luxia Scientific Bacterial combinations predictive of the activity of multiple sclerosis
EP3838276A1 (en) * 2019-12-17 2021-06-23 Exeliom Biosciences Association of faecalibacterium prausnitzii strain cncm i-4573 with pentasa® for the treatment and prevention of gastrointestinal inflammation
US20220408780A1 (en) * 2020-02-11 2022-12-29 The E. Wolfson Medical Center A method effective for treating ulcerative colitis
US20230087012A1 (en) * 2020-02-14 2023-03-23 Cornell University Transferable microbiota for the treatment of ulcerative colitis
CN111304120B (zh) * 2020-02-24 2021-07-23 浙江大学 Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用
EP3875098A1 (en) * 2020-03-04 2021-09-08 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
CN115697084A (zh) * 2020-04-01 2023-02-03 沃尔夫森医疗中心 溃疡性结肠炎膳食、配方、产品及其方法
US20230256033A1 (en) * 2020-06-09 2023-08-17 Flagship Pioneering Innovations Vi, Llc Physiologically acceptable compositions containing microorganisms or microbial products
KR102169795B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도
KR102169794B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
WO2022026873A1 (en) * 2020-07-30 2022-02-03 Bactana Corp. Methods and compositions for treating metabolic conditions
CN111888381A (zh) * 2020-09-18 2020-11-06 广西细微生物科技有限责任公司 一种肠道微生物移植工艺
KR102700146B1 (ko) * 2020-09-28 2024-08-28 씨제이바이오사이언스 주식회사 미생물을 포함하는 염증성 질환 진단 또는 치료용 조성물
US20220326255A1 (en) * 2021-04-01 2022-10-13 Medibeacon Inc. Methods of monitoring mucosal healing
EP4082545A1 (en) * 2021-04-27 2022-11-02 Diotheris Combination product and methods for preventing the emergence of antibiotic-resistant bacteria under antibiotic treatment
KR102337993B1 (ko) * 2021-10-27 2021-12-14 주식회사 바이오뱅크힐링 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN113974159B (zh) * 2021-11-02 2023-06-27 美益添生物医药(武汉)有限公司 齿叶乳香树树脂在制备促进肠道有益菌增殖的产品中的应用
TW202400235A (zh) * 2022-05-13 2024-01-01 國立大學法人東京大學 治療或診斷炎症性腸疾病(ibd)之方法及組合物
CN115944655A (zh) * 2023-02-14 2023-04-11 上海奇诺普森生物科技有限责任公司 一种肠菌组合物及其在防治自闭症中的应用
CN119970806B (zh) * 2025-02-25 2026-03-03 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用
CN119709558B (zh) * 2025-02-26 2025-05-30 昆明医科大学第一附属医院(云南省皮肤病医院) 布劳特氏菌emf75-02b1b及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1510821A1 (en) * 2003-08-27 2005-03-02 Universiteit Utrecht Holding B.V. Diagnosis and treatment of mycobacterial infections
PH12013500224A1 (en) * 2010-08-04 2013-04-08 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
MX2013010343A (es) * 2011-03-09 2014-04-30 Univ Minnesota Composicion y metodos para el transplante de microbiota de colon.
ES2662793T3 (es) * 2011-09-14 2018-04-09 Nubiyota Llc Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos
EP2914135A1 (en) * 2012-11-01 2015-09-09 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
CA2899925A1 (en) * 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
CN105228635A (zh) * 2013-03-05 2016-01-06 格罗宁根大学 Faecalibacterium prausnitzii HTF-F(DSM 26943)在抑制炎症中的应用
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
US9783858B2 (en) * 2014-04-02 2017-10-10 Northwestern University Altered microbiome of chronic pelvic pain
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Similar Documents

Publication Publication Date Title
JP2019520340A5 (https=)
Ojetti et al. The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial
Bergogne-Berezin Treatment and prevention of antibiotic associated diarrhea
AU2010339573B2 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
US20210030818A1 (en) Compositions for use in balancing microbiome
JP2016529309A5 (https=)
JP2019525944A5 (https=)
RU2011139211A (ru) Бактериальные штаммы, обладающие высокой противовоспалительной активностью
JP2015519329A5 (https=)
CA3011977A1 (en) Treatment for modulating gut microbiota
BR112020019979A2 (pt) Composições e métodos para tratamento de doenças inflamatórias intestinais
US11801275B2 (en) Compositions and methods for common colds
CN116367823A (zh) 直接递送维生素以抑制微生物病原体
WO2018187467A1 (en) Compositions and methods for treating parkinson's disease (pd) and related disorders
ITMI950378A1 (it) Associazioni di fermenti lattici e lisati di saccaromiceti loro uso terapeutico e composizioni che le contengono
CN114585380A (zh) 胃肠健康组合物
US20190374586A1 (en) Mrsa infection protective agent
Schultz et al. Escherichia coli Nissle 1917
WO2021097288A1 (en) Compositions and methods for treating neurodegenerative diseases
CN111491643B (zh) 预防或治疗耐药感染的含益生菌和益生元的药物组合物
US20230404970A1 (en) Direct delivery of vitamins to rebalance gut microbiome after exposure to antibiotics
CN111436612A (zh) 一种体内酵素及其制备方法与在抑制新型病毒方面的应用
RU2614730C1 (ru) Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
Telaku et al. Impact of Lactobacillus Reuteri and Three Other Probiotics in Helicobacter Pylori Eradication. Open Access Maced J Med Sci. 2022 Oct 27; 10 (B): 2215-2219
EP3979834B1 (fr) Composition comprenant une levure pour la prevention de la cystite simple et/ou recidivante